Oral HAE treatment is now FDA-approved. On July 7, 2025, Sebetralstat (Ekterly®) became the first oral on-demand therapy for acute attacks in hereditary angioedema (HAE), marking a major shift in how this rare condition is managed. Hereditary Angioedema (HAE) is a rare genetic disorder that causes unpredictable, recurrent episodes of swelling, often affecting the face, throat, gastrointestinal tract, and extremities. If untreated, these attacks can be life-threatening. Until recently, on-demand treatment for HAE required injections only. While berotralstat (Orladeyo®) became the first oral medication approved for prophylaxis in 2020, acute…
Read MoreSebetralstat: The First Oral Treatment for HAE Approved by FDA
